Random C-peptide in the classification of diabetes

REFERENCES

• Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis, and classifica-tion of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15: 539–53.
   Google Scholar
• Landin-Olsson M, Nilsson KO, Lemmark Aring, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990; 33: 561–8.
   Google Scholar
• Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care 1990; 13: 992–1005.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM. Problems related to definition and epidemiology of type 2 (non-insulin-depen-dent) diabetes mellitus: studies throughout the world. Diabetologia 1993; 36: 978–84.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Matsuda A. Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 1997; 20: 219–20.
   PubMed Web of Science ®Google Scholar
• McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus—do we need new criteria? Diabetologia 1997; 40: 247–55.
   PubMed Web of Science ®Google Scholar
• Clark PM. Assays for insulin, proinsulin(s), and C-peptide. Ann Clin Biochem 1999; 36: 541–64.
   PubMed Web of Science ®Google Scholar
• Hoekstra JBL, Van Rijn HJM, Erkelens DW, Thijssen HH. C-peptide. Diabetes Care 1982; 5: 438–46.
   PubMed Web of Science ®Google Scholar
• Canivet B, Krebs BP. C-peptide uptake and excretion by the liver in man. Horm Metab Res 1980; 12: 229–30.
   PubMed Web of Science ®Google Scholar
• Gjessing HJ, Matzen LE, Faber OK, Froland A. Fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989; 32: 305–11.
   PubMed Web of Science ®Google Scholar
• Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. Plasma and urinary C-peptide in the classification of adult diabetics. Scand J Clin Lab Invest 1986; 46: 655–63.
   PubMed Web of Science ®Google Scholar
• Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes dura-tion, metabolic control and 13-cell function in representative population of type 2 diabetic patients in Sweden. Diabetic Med 1994; 11: 794— 801.
   Google Scholar
• Beischer W, Kerner W, Raptis S, Keller L, Beischer B, Pfeiffer EF. Insulin therapy in relation to circulating C-peptide levels. Diabetes 1978; 27 Suppl 1: 235–40.
   PubMed Web of Science ®Google Scholar
• Webb PG, Bonser AM. Basal C-peptide in the discrimination of type I from type II diabetes. Diabetes Care 1981; 4: 616–9.
   PubMed Web of Science ®Google Scholar
• Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I, Binder C. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153–6.
   Google Scholar
• Hother-Nielsen 0, Faber OK, Schwartz Sorensen N, Beck-Nielsen B. Classification of newly diag-nosed diabetic patients as insulin-requiring or non-insulin requiring based on clinical and biochemical variables. Diabetes Care 1988; 11: 531–7.
   Google Scholar
• Escobar-Jimenes F, Herrera Pombo JL, Gomez-Villalba R, Nunez del Carril J, Aguilar M, Rovira A. Standard breakfast test: an alternative to glucagon testing for C-peptide reserve. Horm Metab Res 1990; 22: 339–41.
   Google Scholar
• Heding LG. Kasperska-Czyzykowa T: C-peptide and proinsulin after oral glucose. Acta Med Scand 1980; 639 Suppl: 33–6.
   Google Scholar
• Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark Aring, Sundkvist G. 13-cell function in relation to islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993; 16: 902–10.
   PubMed Web of Science ®Google Scholar
• Arnqvist HJ, Littorin B, Nystr6m L, Schersten B, Ostman J, Blohme G, Lithner F, Wibell L. Difficulties in classifying diabetes at presentation in young adults. Diabetic Med 1993; 10: 606–13.
   PubMed Web of Science ®Google Scholar
• Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977; 26: 605–10.
   Google Scholar
• Garcia-Webb P, Bonser A, Welborn TA. Correla-tion between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus [Letter]. Diabetologia 1982; 22: 296.
   Google Scholar
• Berger B, Stenstr6m S, Chang Y-F, Sundkvist G. The prevalence of diabetes in a Swedish popula-tion of 280 411 inhabitants: a report from the Skaraborg Diabetes Registry (SDR). Diabetes Care 1998; 22: 546–8.
   Google Scholar
• Berger B, Stenström G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population. Diabetes Care 1999; 22: 773–8.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser. no. 727).
   Google Scholar
• Rönnemaa T. Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Lab Invest 1986; 46: 345–9.
   PubMed Web of Science ®Google Scholar
• Nosari I, Lepore G, Maglio ML, Cortinovis F, Pagani G. The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes. J Endocrinol Invest 1992; 15: 143–6.
   Google Scholar
• Forsström JJ. Användningen av ROC-kurvor for mätning och jämförelse av den diagnostiska förmágan hos test. Anvisningar f6r icke para-metral statistisk granskning. In Klinisk Kemi i Norden 1995; 3: 89–97.
   Google Scholar
• Beck JR, Shultz EK. The use of Relative Operating Characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986; 110: 13–20.
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.
   PubMed Web of Science ®Google Scholar
• Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, ()Brien PC, Melton U. The classification of diabetes by clinical and C-peptide criteria. Dia-betes Care 1997; 20: 198–201.
   PubMed Web of Science ®Google Scholar
• Faber OK, Binder C. B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 1977; 13: 263–8.
   PubMed Web of Science ®Google Scholar
• Grant PJ, Barlow E, Miles DW. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy. Diabet Med 1984; 1: 284–6.
   Google Scholar
• Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. C-peptide determination in the choice of treatment in diabetes mellitus. ScandJ Clin Lab Invest 1985; 45: 589–97.
   PubMed Web of Science ®Google Scholar
• Inukai T, Matsutomo K, Tayama YA, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107: 40–5.
   PubMed Web of Science ®Google Scholar
• Expert Committee on the Diagnosis Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183— 97.
   PubMed Web of Science ®Google Scholar